GCM
CTKB icon

Glenview Capital Management’s Cytek Biosciences CTKB Stock Holding History

Glenview Capital Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-500,000
Closed -$5.37M – 56
2022
Q2 		$5.37M Buy
500,000
+444,587
+802% +$4.43M 0.13% 50
2022
Q1 		$597K Buy
+55,413
New +$748K 0.01% 60

Other funds holding CTKB

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Glenview Capital Management's CTKB Position: Q3 2022 in Review

Glenview Capital Management sold out of Cytek Biosciences (CTKB) in Q3 2022, closing a stake of 500,000 shares — an estimated $5.37M sold.

Glenview Capital Management first reported a position in CTKB in Q1 2022 and held it in 2 quarters. The position peaked at $5.37M in Q2 2022. 88 funds tracked by Wall St. Rank hold CTKB as of Q3 2022.

  • Glenview Capital Management reported no remaining Cytek Biosciences position as of Q3 2022 after selling out during the quarter.
  • Glenview Capital Management sold 500,000 Cytek Biosciences shares in Q3 2022, an estimated $5.37M.
  • Glenview Capital Management first reported a position in Cytek Biosciences in Q1 2022 and held it in 2 quarters.
  • Glenview Capital Management's Cytek Biosciences position peaked at $5.37M in Q2 2022.
  • 88 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2022.

Based on Glenview Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.